|
|
Article: Rigel's R112 Demonstrates Robust Effect in Reducing Symptoms of Allergic Rhinitis in Large Phase II Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- August 2, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- R112 Shows Rapid Onset and Sustained Effect in Treatment of Allergic Rhinitis -
- Management Will Host Conference Call at 4:30 PM Eastern Today -
Rigel Pharmaceuticals, Inc. today announced the successful results of a Phase II clinical study evaluating the use of R112, for the treatment of the symptoms of allergic rhinitis. The day one data indicated that R112 reduced the Global Nasal Allergy Symptom Score by 7.0 points (38%) versus 5.4 points (29%) for placebo (p=0.0005), an absolute difference of 9%, and a relative improvement over placebo of 24%. Results on day two were of similar magnitude (p=0.0016).
The randomized, placebo-controlled ...